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Glioma stem cells1. Introduction
The vacuolar ATPase (V-ATPase) is a multisubunit proton pump that
plays a role in multiple processes in eukaryotic cells. It comprises a
membrane-embedded V0 sector, which regulates proton permeability,
and an enzymatic V1ATPase sector. Regulated assembly of theV1 sector
on the V0 sector, alongwithmodulation of ATPase activity, are themain
determinants of pump efﬁciency. The core function of V-ATPase is acid-
iﬁcation of endosomes and lysosomes, two organelles crucial for
proteostasis and metabolism of cellular nutrients. In addition, in bone,
kidney and gut cells, a plasma membrane localized V-ATPase acidiﬁesn, Italy.
), valentina.vaira@unimi.it
. This is an open access article under
lini, C. Martelli, et al., Speciﬁc
ne, https://doi.org/10.1016/j.ethe extracellular milieu and enables speciﬁc functions. The pump local-
ization is regulated by the use of speciﬁc subunits alternative to the ones
present in intracellular compartments [1].
Altered V-ATPase activity is associated with several human diseases
[2]. In cancer, the role of V-ATPase is complex and likely context-
dependent. Tumor cells are exquisitely sensitive to V-ATPase inhibition,
indicating that V-ATPase activity is more limiting in cancer than in non-
cancer cells. Upon V-ATPase inhibition, changes in cytosolic pH stabilize
proapoptotic proteins, alter trafﬁcking of extracellular nutrients, or re-
verse V-ATPase-induced drug resistance [3]. Overexpression of
V-ATPase occurs in a number of cancer cell lines and tumor samples. V-
ATPase may also be involved in modulating the activity of endocytic fac-
tors such as Rac1 andEGFR,which are crucial for cellmotility [4]. Invasive
cancer cells gain expression of V-ATPase at the plasmamembrane, possi-
bly to facilitate low pH-induced activation of proteases that modify the
extracellular matrix. Delivery of V-ATPase speciﬁcally to the plasma
membrane of breast cancer cells relies on overexpression of the V0A3the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
Molecular characterization of gliomas has significantly improved
patients' stratification. However, IDH-wild type lower-grade glio-
mas remain a heterogeneous class with variable outcome. Recent
evidence highlighted preferential use of specific vacuolar H + -
ATPase pump subunits by cancer cells to activate oncogenic path-
ways and overexpression of specific subunits in cancer stem cells.
Added value of this study
Weshow that the expression of specific V-ATPase subunits by gli-
omas determines cancer aggressiveness in vivo and predicts pa-
tient prognosis, also in IDH-wild type lower-grade gliomas. The
oncogenic V-ATPase profile associates with homeobox-
containing genes overexpression.
Implications of all the available evidence
Evaluation of the level of expression of selected V-ATPase sub-
units in IDH-wild type lower-grade gliomas could complement rou-
tine molecular characterization to identify patients with most
aggressive forms of the disease. Moreover, our data suggest
that V-ATPase could be a novel interesting therapeutic target in
a fraction of gliomas.
2 A. Terrasi et al. / EBioMedicine xxx (2019) xxxsubunit, which is normally speciﬁc to osteoclasts; this suggests that
changes in pump subunit composition support cancer-speciﬁc functions
[5]. Despite the fact that the role of V-ATPase in cancer is diverse and in-
sufﬁciently understood, the emerging evidence strongly suggests that V-
ATPase could be a promising target for anticancer therapy.
Glial tumors are among the most difﬁcult to proﬁle and treat. The
2016 WHO classiﬁcation of gliomas changed disease diagnosis and pa-
tient stratiﬁcation markedly, shifting from a morphological view to a
molecular-based classiﬁcation [6]. In this new context, mutated
isocitrate dehydrogenase 1 or 2 enzymes (IDHmut) are a major classi-
ﬁer of disease, aswell as being key genetic events during gliomagenesis.
IDH wild-type (IDHwt) tumors have a dismal outcome and are gener-
ally regarded as glioblastoma (GBM), even when they are histologically
classiﬁed as lower-grade grade II and III gliomas. Nevertheless, a recent
study shows that adult IDHwt lower grade gliomas (LGG/IDHwt) are
prognostically and molecularly heterogeneous, meaning that not all
are characterized by a poor, GBM-like outcome [7].
We showed previously that the G1 subunit of V-ATPase V1 sector
(V1G1) is upregulated in primary stem cell-enriched cultures of GBM
neurospheres (NS), and that higher expression of this subunit identiﬁes
glioma patients with shorter disease-free and overall survival indepen-
dent of clinical or molecular variables [8]. These data suggest that
changes in V-ATPase composition, and possibly activity, promote GBM
aggressiveness and maintain the cancer stem cell niche. However, the
signiﬁcance of changes in V-ATPase subunits in GBM is unknown.
Therefore, to identify the mechanisms underlying glioma aggres-
siveness, alongwith novel and clinically relevantmarkers, we examined
all V-ATPase subunits and associated signaling pathways, focusing on
the less characterized LGG/IDHwt class.
2. Materials and methods
2.1. Patients' series
TCGA dataset: Data from the TCGA glioma cohort was downloaded
from TCGA portal (Jay 2015 release; https://tcga-data.nci.nih.gov/Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.edocs/publications/lgggbm_2015/). Brieﬂy, the lower-grade gliomas
(LGG) and glioblastoma (GBM) dataset consisted in 1032 diffuse glio-
mas and 12,717 genes. Of these, we included in our study only tumors
for which RNAseqV2 analysis was performed and with clinical and mo-
lecular annotation [9]. Cases with mutated IDH1 or 2 were considered
IDHmutant (IDHmut). Therefore we included 481 patients, of whom
330 were LGG/IDHmut, 73 were de novo GBM (i.e. IDHwt cases only)
and 76 were LGG/IDHwt cases. LGG/IDHmut and GBM cases constitute
our training set, whereas LGG/IDHwt cases represent the test set. De-
tailed patients' information are reported in Tables S1,S2.
Primary and recurrent LGG cohort: This series consisted in 23 pri-
mary and treatment-naïve LGG patients and in 21 unmatched relapsed
gliomas, which evolved from LGG disease to higher grade glioma. Pa-
tients' characteristics are detailed in Table S3. All patients received a
gross total resection of the tumor at Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico between 2013 and 2016. None of the
patients included in the study received a biopsy or neoadjuvant
therapy. The study was approved by an Institutional Review Board
(IRB#275/2013) and signed informed consent was obtained from all
patients.
Matched primary and recurrent gliomas (n = 28; TCGA_LGG data
source) were also analyzed through the GlioVis portal, (http://gliovis.
bioinfo.cnio.es/) for V-ATPase expression.
Gravendeel dataset: Gene expression data (19,944 genes, Affymetrix
GeneChip HumanGenomeU133 Plus 2.0 Array) and clinicopathological
correlates from LGG/IDHmut (n= 72), GBM (n= 159) and LGG/IDHwt
(n = 41) cases [10,11] were retrieved from the GlioVis portal. Only
IDH1mutation statuswas available for this dataset. Grade I, pilocytic as-
trocytomas (n = 4), were used only for heatmap generation and were
excluded from ROC analysis. As for the TCGA cohort, LGG/IDHmut and
GBM constituted the training set (Table S4), whereas the LGG/IDHwt
cases constituted the validation set (Table S5).
2.2. Primary, patients-derived or commercial cell cultures
GBM neurospheres (NS, n = 33) or differentiated cultures were ob-
tained from fresh tumor tissue of GBMpatients (Table S6) as previously
described [8]. All patients were enrolled at the Division of Neurosurgery
and glioma was diagnosed at the Division of Pathology of the
Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico (Milan,
Italy). All caseswere reviewed and graded by senior pathologist (SB) ac-
cording to the new classiﬁcation of the World Health Organization [6].
Brieﬂy, tissues underwent enzymatic and mechanical dissociation di-
gestion in serum-free media using the Tumor Dissociation kit
(Miltenyi). Then, cells suspensions were washed twice with HBSS
(Gibco-Invitrogen, Thermo Fisher Scientiﬁc, Waltham, MA USA) and ei-
ther seeded in NeuroCult (NC) media supplemented with growth fac-
tors (Proliferation Supplement, bFGF and EGF, all from Voden) to
promote growth of stem cells (undifferentiated condition) or in RPMI
supplemented with 10% Exo-FBS (System Biosciences) to promote cell
differentiation.
2.3. DNA puriﬁcation and targeted sequencing
We analyzed the mutation status of 28 cancer-related genes in our
primary NS by targeted sequencing using a custom designed panel (n.
of amplicons: 657; coverage 99%; Table S7). Brieﬂy, genomic DNA was
puriﬁed from 8 NS with high (namely NS#27,91,92,97) or low (namely
NS#51,53,88,130) V-ATPase G1 expression using the DNeasy Blood &
Tissue Kits (Qiagen, Hilden, Germany). Libraries for Illumina sequencing
were constructed from 100 ng of total DNA with the TruSeq Custom
Amplicon Low Input Library Prep Kit v2 (Illumina, San Diego, CA,
USA). Paired-end sequencing (2 × 150) was then performed on an
Illumina miSeq instrument. Reads were processed and aligned against
the GRCh37Hg19 human reference genome by the MiSeqReporter soft-
ware (Illumina). Variant calling ﬁle (VCF) for each sample were thenV-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
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tion and ﬁltering using the ANNOVAR package (http://annovar.
openbioinformatics.org/en/latest/). Thresholds for somatic mutation
calling were: an allele depth value ≥30 reads; a variant frequency N
0·03; the variant should not be detected in N5% of healthy population
(available from ExAC portal; http://exac.broadinstitute.org/) [12].2.4. Generation of GBM patients' derived orthotopic mouse model
Animal experiments were carried out in compliance with the insti-
tutional guidelines for the care and use of experimental animals
(European Directive 2010/63/UE and the Italian law 26/2014), autho-
rized by the Italian Ministry of Health and approved by the Animal
Use and Care Committee of the University of Milan. Female NOD/SCID
mice (7–8 weeks of age, Envigo, Huntingdon, UK) were kept in the ap-
propriate cages in an environment of 23 ± 1 °C and 50 ± 5% humidity,
with a 12 h light/dark cycle and fed ad libitum. The orthotopic murine
model was obtained by stereotaxic injection (coordinates: 1.5 mm lat-
eral to the bregma, 0 mm behind and 3·0 mm ventral to the dura) of
1 × 10^5 patients derived NS stably transduced with a luciferase con-
struct in 2 μl of phosphate-buffered saline (PBS) as described [13]. Fol-
lowing surgery, mice were monitored for recovery until complete
awakening. For bioluminescence imaging, mice were anaesthetized
with mixture of tiletamine/zolazepam (40 mg/kg, Zoletil) and xylazine
(8mg/kg, Xilor), and then 150mg/kg of luciferin (Beetle Luciferin Potas-
sium Salt, Promega) was injected intraperitoneally. After
biodistribution, bioluminescence signal (BL) was acquired with the
IVIS SPECTRUM/CT instrument (Perkin Elmer), always using the same
parameters. Finally, all images were scaled and quantiﬁed by applying
Regions of Interest (ROI) on BL signals using the Living Image Software.
Data are expressed as BL counts. All animals were sacriﬁced at day 109
and their brain was recovered for histological examination.2.5. Drosophila melanogaster experiments
Fly strainswere kept and raised invials containing standard foodme-
dium. All crosses were performed at 25 °C. To assess larval brain over-
growth phenotypes, larvae were grown for 120–140 h, and wandering
3rd instar larvaewere selected for dissection. The genotypes of the Dro-
sophila lines used in the study are: a); Repo-Gal4, UAS-CD8GFP, TM2;
b) UAS-Pi3K92E-CAAX; Repo-Gal4, UAS-CD8GFP, UAS-ΔhEGFR,TM6C
TubGal-80 (kindly provided by Renee Read); c) UAS-VhaPPA1–1 RNAi
(v47188, from theVienna Stock Center). The immunoﬂuorescence anal-
ysis was performed as follows: larval brainswere ﬁxed using 4% PFA for
30 min at room temperature. Permeabilization was performed with 1%
Triton X-100 diluted in PBS, for 30 min. Samples were blocked in 4%
BSA, 0·1% Triton X-100 diluted in PBS for 30 min at room temperature.
The primary antibody anti-GFP (1:1000; 13,970, Abcam)was incubated
on at 4 °C. The Alexa Fluor 488-conjugated (1:500; A-11039, Thermo
Fisher Scientiﬁc) secondary antibodywas incubated at RT for 2 h. Tissues
weremounted in glycerol and imageswere takenwith a TCS SP5micro-
scope (Leica, Heidelberg, Germany) using 20×/NA 0·5, oil-immersion
lenses and measurements were carried out with ImageJ software
(https://imagej.nih.gov/ij/). To extract RNA from Drosophila L3 larval
brains we used Maxwell RSC simplyRNA Tissue Kit and the
Maxwell RSC Instrument. The concentration of extracted RNAwasmea-
sured using the NanoDrop 1000 Spectrophotometer. Complementary
DNA (cDNA) synthesiswas performed SuperScript VILO cDNASynthesis
Kit and qPCR was carried out on the ABI/Prism 7900 HT Sequence
Detector System (Thermo Fisher Scientiﬁc). The following primers
(5′-3′) were selected from the Universal Probe Library (Roche):
VhaPPA1–1_fwd: 5′ atcttcggttcggccatc 3′ VhaPPA1–1_rev: 5′
ataatggagtggcgaaggac 3′; RPL32_fwd: 5′ cggatcgatatgctaagctgt 3′
RPL32 rev: 5′ cgacgcactctgttgtcg 3′.Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.e2.6. RNA puriﬁcation and genes expression analyses
Total RNAwas puriﬁed from cell cultures usingMaster Pure RNApu-
riﬁcation kit (Epicentre Biotechnologies, Illumina; Madison, WI, USA)
followed by DNA digestion with DNase I, Ampliﬁcation Grade (Thermo
Fisher Scientiﬁc). Then, 300 ng of DNA-free total RNA from cell cultures
were reverse transcribed using the SuperScript II Reverse Transcriptase,
random hexamers and TaqMan assays (listed in Table S8) (all from
Thermo Fisher Scientiﬁc) in 20 μl or reaction mix. Targets gene expres-
sionwas quantiﬁed by qPCR using TaqMan assays togetherwith the ref-
erence genes β2microglobulin and/or 18S RNA using the 2^(−Delta Ct)
formula. Then, targets relative quantities (RQ)weremedian normalized
and log2-transformed.2.7. Antibodies and reagents
Cathepsin L (941) was from ImmunoChemistry Technologies
(Bloomington, MN, USA). The following primary antibodies were used
for immunohistochemistry, immunoﬂuorescence, and immunoblotting
(IB): V-ATPase G1 (16143–1-AP, Proteintech), V-ATPase V0A2
(SAB2100187, Sigma Aldrich), Vinculin (V9131, Sigma Aldrich), Ki67
(ab15580, Abcam), Podoplanin (D2–40; Ventana Medical Systems,
Roche), MMP2 (10373–2-AP, Proteintech), POU3F2 (12,137, Cell
Signaling), HOXA10 (TA590263, Origen), HOXA7 (ab211521, Abcam),
V-ATPase G2 (25316–1-AP, Proteintech).2.8. Immunoﬂuorescence and immunohistochemistry
For immunoﬂuorescence experiments, NS were cytospinned on
charged slides for 3 min at 900 rpm (Thermo Scientiﬁc, Waltham, MA,
USA). Cells were ﬁrst ﬁxed in PFA 4% for 15 (monolayer cultures) or
30 min (NS), quenched for green auto-ﬂuorescence using glycine
20 mM for 20 min and then permeabilized with Triton 0·5% for
30 min at room temperature. Then, samples were saturated with BSA
10% for 1 h at RT. Primary antibodies (1:100 in PBS-BSA 10%)were incu-
bated overnight at 4 °Cwhereas secondary antibodies (1:1000)were in-
cubated for 1 h at room temperature. Finally, nuclei were stained with
Hoechst 3342 (Cell Signaling) for 5 min at RT and slides were mounted
using the Prolong reagent (ThemoFisher Scientiﬁc). For negative con-
trols, one slide per target protein was incubated with all reagents but
the primary antibody. Confocal images were generated with a Leica
TCS SP5 Confocal microscope (Leica Microsystems) with a magniﬁca-
tion of 40×, and z-stack images were captured every 0·46 μm. Fluores-
cence quantiﬁcation was calculated on full cell stacks after setting the
threshold on control samples, and the mean intensity of the ﬂuoro-
chrome was calculated using ImageJ software. Immunohistochemistry
(IHC) on formalin-ﬁxed parafﬁn-embedded samples was performed
using a Ventana Benchmark instrument and the Ultraview DAB or Red
Detection kits as described [8].2.9. Immunoblotting
Protein extracts were prepared in RIPA buffer supplemented with
phosphatase and protease inhibitors (Roche). After lysis, samples
were sonicated ﬁve times on ice (Bioruptor Plus sonication device,
Diagenode), pelleted at 15·000rcf to remove debris and quantiﬁed
using microBCA kit (Thermo Fisher Scientiﬁc). Proteins (40 μg)
were boiled for 5 min at 95°, resolved by SDS-PAGE, transferred to
nitrocellulose membrane, blocked in 5% not-fat powdered milk in
PBS-T (1% Tween-20) and probed with antibodies. Proteins bands
were then visualized using the Amersham ECL Prime Western Blot-
ting Detection Reagent (GE Healthcare) and the LAS-3000 imager
(Fujiﬁlm).V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
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Gene expression data ﬁltering: For RNASeq data, we used previ-
ously normalized counts available from the TCGA portal. We included
transcripts whose log2 expression level (normalized counts) was N5
in the top tenth percentile of the patients dataset (n = 7321 out of
12,717, 58%). For the Gravendeel dataset (Affymetrix platform) we
used previously normalized and log2 transformed data available in
GlioVis portal.
Gene expression data visualization: Transcripts' levels of V-ATPase
subunits and of differentially expressed genes were visualized in glio-
mas using the ComplexHeatmap package available in Bioconductor
(https://bioconductor.org/packages/release/bioc/html/
ComplexHeatmap.html). Principal component analysis (PCA) plots
were generated in R (https://cran.r-project.org/) to visualize gliomas
distribution according to speciﬁc genes signatures (V-ATPase or differ-
entially expressed genes as indicated in ﬁgures' legends). Notched
box-and-whiskers plot (MedCalc software) was used to show expres-
sion of homeobox genes in Gravendeel LGG/IDHwt cases belonging to
the two V-ATPase classes. Brieﬂy, all data points are shown as dots
along with the central box (values from the 25 to 75 percentile), the
middle line (median) and the extremes (min-to-max values) unless
otherwise speciﬁed.
Identiﬁcation of prognostic V-ATPase or “other” genes signatures:
All V-ATPase transcripts expressed above the threshold (n = 15) were
analyzed for differential expression in LGG/IDHmut and GBM cases of
the TCGA training series using the Kolmogorov–Smirnov test and com-
puting the fold-change (Log2Ratio, L2R) between the two classes. The
accuracy of the data was assessed by a permutation-based estimate of
the FDR. For each pair of chosen Kolmogorov–Smirnov p values and FC
thresholds, the FDR was computed reshufﬂing 1000 times. Genes with
an adj p b 10–5 and a L2R ≥ |0·3| were considered signiﬁcant (n = 8).
Then, to identify which V-ATPase gene or set of genes best discrimi-
nated LGG/IDHmut from GBM cases (training set) we performed a Re-
ceiver Operating Characteristic (ROC) analysis survey with
signiﬁcantly different V-ATPases or the combined top 3 or top 4Fig. 1.V-ATPase pump conformation distinguishes aggressive gliomas from indolent LGG a) Exp
low-grade/IDH-mutated gliomas (LGG/IDHmut; n = 330) and glioblastoma (GBM; n = 75) fr
LGG/IDHmut or GBM based on gene expression data determined in a.V0B encodes for subunit
Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.edown- or u-regulated subunits. For cut-off identiﬁcation the Youden's
J statistic was used as described [8].
The adj p b 10–5 and a L2R ≥ |0·5| was used when the whole tran-
scriptome (n = 3417) was queried for genes differentially expressed
between the two gliomas' classes and for the Gravendeel series of gli-
omas. ROC analyses were performed using the ROCR package avail-
able within the R environment (http://rocr.bioinf.mpi-sb.mpg.de/).
The identiﬁed cut-offs (J index) from the best ROCswere then applied
to categorize the LGG/IDHwt patients as LGG/IDHmut-like or GBM-
like.
Survival analysis: The impact of clinicopathological or molecular
variables or of the V-ATPase classiﬁcation on overall survival status of
LGG/IDHwt patients was analyzed by univariate analysis using the Cox
proportional-hazards regression model. Only variables with a p b 0·05
were included in the multivariate model. Kaplan-Meier survival curves
were then generated with LGG/IDHwt patients sorted into the two
V-ATPase classes. All analyses were performed usingMedCalc software.
Identiﬁcation and functional annotation of genes associated to
V-ATPase signatures: Genes associated with each of the V-ATPase class
were searched in LGG/IDHwt series and then veriﬁed in LGG/IDHmut
and GBM cases. Genes were compared using the Kolmogorov–
Smirnov test followed by a permutation-based estimate of the FDR. A
gene was considered differentially expressed if with an FDR adjusted
p b 10–5 and a L2R ≥ |2|. Lists of genes enriched in the V-ATPase
LGG/IDHmut-like or GBM-like class were created and analyzed using
DAVID functional annotation tool (https://david.ncifcrf.gov/). Networks
of top pathways were generated using ConsensusPathDB (http://cpdb.
molgen.mpg.de/) selecting gene set analysis/enrichment analysis
terms. The search was performed in all databases.
Analysis of functional experiments: Data from functional experi-
ments were imported in GraphPad Prism software (La Jolla, CA, USA)
and analyzed using the non-parametric Mann-Whitney U and
Kruskal-Wallis tests for two-sample or more than two-sample compar-
isons, respectively. Data are presented asmean±SEMand experiments
were performed at least three times and in technical duplicate unless
otherwise speciﬁed. In particular, experiments involving patients'ression (RNAseq data) of genes encoding all V-ATPase pump subunits (n= 20) in primary
om the TCGA dataset (training set). b) Cartoon showing V-ATPase pump conformation in
c”.
V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
biom.2019.01.052
5A. Terrasi et al. / EBioMedicine xxx (2019) xxx
Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019.01.052
6 A. Terrasi et al. / EBioMedicine xxx (2019) xxxderived NS were performed with ﬁve V1G1High- and ﬁve V1G1Low- NS
in triplicate. Categorical data were analyzed using chi square test.
P values b0·05 were considered statistically signiﬁcant.
3. Results
3.1. GBM are characterized by expression of speciﬁc V-ATPase pump
subunits
Previously, we showed that V1G1 is enriched in primary cultures of
GBM neurospheres (NS), and that higher expression of this subunit
identiﬁes glioma patients with shorter disease-free and overall survival,
independent of other clinical ormolecular variables. To conﬁrmour pre-
vious data on differential V-ATPase subunit expression [8], we ﬁrst
assessed the expression of V1G1NS and found that it correlateswith ex-
pression of genes related to stemness (Fig. S1a), ability of primary GBM
cultures to form NS with high proliferative activity (Fig. S1b), increased
expression of the proteolytic enzyme MMP2 (Fig. S1c) and of cathepsin
L activity (Fig. S1d).
Interestingly, no speciﬁc mutation in key glioma genes was associ-
ated with V1G1 overexpression in NS (Table S9).We then sought to un-
derstand which V-ATPase subunits are deregulated in aggressive GBM,
when compared with indolent IDH-mutant lower grade gliomas (LGG/
IDHmut). Using data available from the TCGA database, we analyzed ex-
pression of V-ATPase genes (training set; Fig. 1a). As hypothesized, V-
ATPase subunits varied greatly between the two glioma types. Interest-
ingly, we could observe an alternative expression of pump subunits by
aggressive GBM relative to LGG. GBM expressed ATP6V1G1 (encoding
V1G1) rather than ATP6V1G2 (V1G2); ATP6V0A2 (V0A2) rather than
ATP6V0A1 (V0A1) or ATP6V0A4 (V0A4); and ATP6V0E1 (V0E1) rather
than ATP6V0E2(V0E2). In addition, some core and regulatory subunit
genes, such as ATP6V1A (V1A), ATP6V1H (V1H), and ATP6V1C (V1C),
were downregulated in GBM, whereas ATP6V0B (V0B) was upregulated
(Fig. 1a). These changes in gene expression denoted glioma type-
speciﬁc pump conﬁgurations (Fig. 1b).
3.2. Deregulation of V-ATPase affects gliomagenesis in vivo
To test whether V-ATPase activity is required to support
gliomagenesis in vivo, we ﬁrst used a Drosophila glioma model based
on overexpression of constitutively active forms of Drosophila PI3K
(Pi3K92E-CAAX [14];) and of the human Epidermal Growth Factor Re-
ceptor (ΔEGFR) in larval glial cells (Fig. 2a). In this model, we found
that down-regulation of V-ATPaseV0 c”, encoded by VhaPPA1–1 (the
ﬂy homolog of ATP6V0B;Fig. 2a,b) reduced tumor size up to control
levelswithout affecting growth on anotherwisewild-type genetic back-
ground (Fig. 2c, d).
Next, we conﬁrmed these data in an orthotopic mouse model of gli-
oma. Importantly, we found that NS showing endogenous high expres-
sion of V-ATPaseG1 (V1G1High) were more tumorigenic in vivo than NS
V1G1Low (Fig. 2e, f). Gliomas generated from V1G1High NS completely
invaded the normal brain parenchyma of mice (as shown by STEM121
staining; Fig. 2g) and had a higher proliferation index (Ki67; Fig. 2h)
than tumors derived from NS V1G1Low. Overall, these data indicate
that the levels of V-ATPase expression affect glioma growth in vivo.Fig. 2. V-ATPase levels determine glioma growth in vivo. a–d) Down-regulation of VhaPPA1–1 p
whole brains from 3rd instar larvae. Dorsal view, anterior up. Glial tissue is labeled by a memb
reverse polarity (repo) gene. Note the increase in CD8GFP expression and brain size in larvae e
which is prevented by downregulating VhaPPA1–1 (repoN CD8GFP ΔEGFR Pi3K92E-CAAX Vh
larvae by qPCR. Bars, means ± s.d. of three independent experiments. c,d) Surface area (c) o
mean ± SEM; **, p b 0·01; ***, p b 0·001 (Kruskal-Wallis test with Dunn's post-test). e, f) G
transfected with a luciferase construct and injected intracranially into nude mice (n = 8 per g
emission (BL counts). **, p b 0·01; ***, p b 0·001 (Kruskal-Wallis test with Dunn's post-test).
and STEM121 stains of brains from mice injected with V-ATPase V1G1 low- (left panels) or
(Ki67 staining) in the brains of indicated mice. (For interpretation of the references to colour i
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We then testes which V-ATPase subunits were differentially
expressed between LGG/IDHmut and GBM cases. Statistical analysis re-
vealed that eight V-ATPase geneswere signiﬁcantly deregulated in LGG/
IDHmut, when compared with GBM (Table S10; Fig. S2). Considering
only LGG/IDHmut cases, V1G2, V0A1, V1C1, and V1Awere also downreg-
ulated in cases without 1p/19q co-deletion, whereas V1F and V0Bwere
upregulated (Fig. 3a).
Next, we analyzed these eight pump subunits in our series of pri-
mary or relapsed LGG cases (Fig. 3b), and in LGG cases forwhich expres-
sion data regarding matched primary and recurrent disease were
available in the GlioVis portal (Fig. 3c) [10]. In both analyses, relapsed
tumors showed down-regulation of V1G2 and upregulation of V1G1
(Fig. 3b, c). Furthermore, imbalances between the two catalytic subunits
in terms of sphere-forming efﬁciency were observed in GBM tissues
used to generate primary cultures (Fig. S2a), and between primary
GBM cultures maintained in a differentiated or undifferentiated (NS)
state (Fig. S2b). These data suggest the existence of a striking tumor
type-speciﬁc V-ATPase signature.
A gray area in glioma clinicalmanagement is the identiﬁcation of pa-
tients with a GBM-like outcome among those with IDHwt non-co-
deleted LGG (LGG/IDHwt). Although previous studies categorized
most LGG/IDHwt tumors as other types based on complex molecular
analysis [15], their pathobiology, clinical behavior, and, consequently,
prognosis remain highly variable.
Based on the data obtained from GBM and relapsed gliomas, we an-
alyzed the eight V-ATPase subunits in LGG/IDHwt patients available
from the TCGA database (n= 76; Fig. 3d). Consistent with the possibil-
ity that the LGG/IDHwt patient group is heterogeneous, we noted a clear
difference in expression of pump subunits in some cases. Therefore, we
used ROC curve analysis to examine combinations of V-ATPase subunits
to identify those that better classify the training set. The best classiﬁer
was provided by a combination of V1G2, V0A1, and V1C1, all of which
were downregulated in GBM (Table S11; Fig. 3e). LGG/IDHwt patients
were then categorized into two classes, LGG/IDHmut-like or LGG/
GBM-like, based on the ROC-generated cut-off value (Youden J
index≤6·33; Table S11). Principal component analysis (PCA; Fig. 3f)
performed using the three subunit signature showed that the distribu-
tion of LGG/IDHwt samples was inﬂuenced signiﬁcantly by V-ATPase
classiﬁcation, with 95% of sample variance explained by the ﬁrst two
components. Although V-ATPase classiﬁcation of LGG/IDHwt patients
was associatedwith a number of clinico-pathological andmolecular fea-
tures, such as tumor grade, derangement of chromosomes 7/10,methyl-
ation and transcriptome subtypes (Table S12), stratiﬁcation by V-
ATPase expression distinguished LGG/IDHwt patients with a poor prog-
nosis (Fig. 3g), independent of clinical variables (Table 1 and Table S13).
The ability of V-ATPase-based classiﬁcation to identify patients within
the LGG/IDHwt cohort with a poorer prognosis was also evident by
looking at the percentage of deceased patients in the LGG/IDHmut-like
and LGG/GBM-like groups, that was 17% and 48%, respectively (p b
0·0001 by Chi-square test; Fig. 3h).
To verify that identiﬁcation of two classes of LGG/IDHwt patients
with different prognoses was not a false-positive, and that other gene-
based classiﬁcations were not as powerful as the V-ATPase-basedrevents tumor growth in brains of Drosophila larvae. a) Single confocal medial sections of
rane-targeted form of GFP (CD8GFP; green) expressed under the glial speciﬁc promoter of
xpressing ΔEGFR and Pi3K92E-CAAX under repo (repoN CD8GFP ΔEGFR Pi3K92E-CAAX),
aPPA1–1). Scale bar, 100 μm. b) VhaPPA1–1 mRNA was measured in brains of 3rd instar
r GFP pixel intensity (d) quantiﬁcation of brain sections (N6 brains per genotype). Bars,
BM-derived neurospheres (NS) with low or high levels of V-ATPase V1G1 were stably
roup). Tumor growth was monitored over time (up to Day 109) by measuring luciferase
Dots, mean ± SEM (n = 13 per group). g) Representative hematoxylin and eosin (H&E)
high- (right panels) NS at the time of harvesting (Day 109). h) Glioma cell proliferation
n this ﬁgure legend, the reader is referred to the web version of this article.)
V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
biom.2019.01.052
7A. Terrasi et al. / EBioMedicine xxx (2019) xxx
Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.ebiom.2019.01.052
Table 1
Multivariate analysis of LGG/IDHwta.
Covariate p HRb 95% CIc
Age diagnosis 0·002 1·07 1·0–1·1
V-ATPase Class (LGG/IDHmut-like) 0·03 0·27 0·09–0·88
LGmd (cluster 6) 0·87 0·90 0·25–3·19
a Overall model ﬁt: p = .0008.
b HR, Hazard Ratio.
c CI, Conﬁdence Interval.
d Pan Glioma DNA Methylation Cluster (Ceccarelli M. Cell) [9].
8 A. Terrasi et al. / EBioMedicine xxx (2019) xxxclassiﬁcation, we repeated the analyses using as classiﬁer the genes
showing the greatest differential expression between LGG/IDHmut
and GBM patients (n = 3417, L2R = p b 10−5; Fig. S3a), or transcripts
signiﬁcantly downregulated in GBM (n = 2035). Then, we calculated
a ROC cut-off value that differentiated LGG/IDHwt patients into two
groups (Table S11).We then performed PCA analysis to verify the accu-
racy of this classiﬁer (called “Other genes”; Fig. S3b). In this case, sample
groups in PCA were not as distinct as they were for the V-ATPase class
(only 31% or 37% of sample variancewas explained by theﬁrst two com-
ponents; Fig. S3b). Most importantly, these two classiﬁcations were not
prognostic (p = 0·08 and p = 0·25 by Log-Rank test; Fig. S3c, d).
Finally, we validated the three V-ATPase subunits' signature using a
third series of gliomas for which molecular and histological classiﬁca-
tions were available [11]. Again, we observed lower expression of
V1G2, V0A1, and V1C1 in GBM than in the more indolent LGG/IDHmut
cases (Fig. S4a). Expression of the three subunits in LGG/IDHwt and
GBM cases was then used to build a ROC curve to identify a cut-off
value for sorting LGG/IDHwt cases into the two V-ATPase classes. As be-
fore, the non-arbitrary Youden J Index was used (Fig. S4b). PCA analysis
conﬁrmed elevated accuracy of the classiﬁer (89% of total sample vari-
ance explained by the ﬁrst two components; Fig. S4c). Also, and most
importantly, the V-ATPase classiﬁer was prognostic for LGG/IDHwt pa-
tients (p = 0·0003, HR = 3·15, by Log-Rank test; Fig. S4d). Therefore,
we conclude that down-regulation of ATP6V1G2, V0A1, and V1C1 sub-
units is critical to predict glioma aggressiveness.
3.4. The GBM-like V-ATPase proﬁle is associated with de-differentiation and
upregulation of homeobox genes
To gain insight into themolecular phenotype of LGG/IDHwt gliomas
belonging to the two V-ATPase classes, we analyzed the gene signatures
associatedwith the LGG/IDHmut-like or LGG/GBM-like classes (Fig. S5a,
b). Three hundred andﬁfty-nine geneswere differentially expressed be-
tween the two groups (Fig. S5a; Table S14), with themajority (n=309,
86%) being downregulated. Interestingly, this transcriptional proﬁle dif-
ferentiated GBM from LGG/IDHmut cases (Fig. S5b). Functional annota-
tion of this signature (Table S15) showed that genes related to neuronal
processes and signaling were enriched in LGG/IDHmut-like cases
(Fig. 4a). In sheer contrast, LGG/GBM-like cases were characterized by
expression of genes involved in embryogenesis, cancer, and cell-cell sig-
naling (Fig. 4b; Table S16). Interestingly, homeobox genes, mainly the
HOX family, were signiﬁcantly over-represented in LGG/GBM-like
cases (38% and 24% of upregulated transcripts, respectively; Table S14).
Finally, homeobox genes deregulation was conﬁrmed in a third se-
ries of gliomas (Gravendeel dataset; Fig. 4c).
Homeobox genes are key players in glioma progression [16,17] and,
most importantly, in transcriptional reprogramming of stem-like GBM
cells [18] but the connection between homeobox genes and V-ATPase
signaling was only partially explored in non-mammalian systems [19].
In mammalian systems, we observed that the neurodevelopmental ho-
meobox transcription factor POU3F2 is regulated by theV-ATPase inhib-
itor Baﬁlomycin A1 [8]. Therefore, we examined expression of
homeobox genes HOXA7, HOXA10, SHOX2, and POU3F2 in our patient-
derived GBM primary cultures. All of these transcription factors wereFig. 3. V-ATPase pump conformation resolves the heterogeneous class of LGG/IDHwt. a) Eight V
0·00001, and absolute Log2 ratio value N0·3; see Supplemental Table 10). Moreover, differenti
presence/absence of the 1p19q co-deletion. ***, p b 0·0001; **, p = 0·001; *, p = 0·04; §, p =
upper quartile) with whiskers indicating the 10 and 90 percentiles. c) Expression of V-ATPas
represents one sample. *, p = 0·04 (Mann-Whitney U test). d) Processed RNAseq data from
and V-ATPase subunit expression was examined. Signiﬁcance of pairwise comparisons was ob
and upper quartile) with whiskers indicating the minimum and maximum values. e) Heatm
f) ROC curve analysis coupled with the Youden's J statistic was used to identify the best cl
regulation of ATP6V1G2, ATP6V1C1, and ATP6V0A1 provided the best classiﬁcation (sensitiv
IDHmut-like or GBM-like according to the ROC-generated cut-off determined in f. Principal c
classes. h) Survival analysis of LGG/IDHwt patients according to V-ATPase class. i) Percentag
class (for LGG/IDHwt cases). p b 0·0001 (Chi-square test). Mean survival times were 26·7, 19
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tures generated from NS (Fig. 5a). Consistent with our previous obser-
vation of speciﬁc V-ATPase subunit expression in aggressive glioma,
the homeobox proteins were expressed at high levels in NS character-
ized by elevated V1G1 and low V1G2 levels (Fig. 5b, c and Fig. S6a–c).
4. Discussion
Here, we show that the most aggressive adult glioma, GBM, exhibits
a peculiar expression proﬁle of V-ATPase genes that implies use of
pump subunits different from that used by indolent tumors, such as
IDHmut/1p19q co-deleted LGG. Interestingly, this subunit signature is
also present in relapsed disease, in gliomas enriched in cancer stem
cells and with higher tumorigenic potential in vivo. From a clinical
standpoint, such an alternative use of V-ATPase subunits can identify
the patients that have a worse prognosis within the LGG/IDHwt class,
a provisional entity in the current WHO classiﬁcation. Our approach to
stratify the LGG/IDHwt group was conﬁrmed using different public
datasets of patients. At the transcriptional level, the GBM-like V-
ATPase signature correlates with overexpression of developmental
genes, such as the homeodomain-containing transcripts HOXA7,
HOXA10, and POU3F2. Recently, classiﬁcation of adult glioma has
moved from a pure histological assessment to a molecular-based one.
Currently, glioma classiﬁcation relies on determination of the muta-
tional status of IDH1 and 2, followed by co-deletion of 1p/19q, loss of
ATRX, and TP53 mutation. The presence of IDH mutations and 1p/19q
co-deletion deﬁnes the least aggressive subtype of glioma, the
oligodendroglioma. By contrast, wild-type IDH and ATRX genes, and ab-
sence of the 1p/19 co-deletion, are typical of GBM [6]. While this classi-
ﬁcation has signiﬁcantly improved the stratiﬁcation of adult LGG, the
“LGG/IDHwt” group is not fully resolved and requires further investiga-
tion. Former studies show that some of these cases should be
reclassiﬁed asGBM, but not all patients have a uniformly poor prognosis
and a GBM-like outcome [7]. Therefore, a more reﬁned characterization
of LGG/IDHwt is important for patient clinical management after sur-
gery. In this context, the sub-typing of LGG/IDHwt cases according to
the V-ATPase classmight support personalization of the therapeutic ap-
proach, directing only GBM-like patients to intensive therapeutic proto-
cols similar to that followed by GBM patients, such as combination of
both radiation and chemotherapy.
Previously, we reported that V-ATPase G1 is enriched in glioma stem
cells and identiﬁes gliomapatientswith a poorer prognosis [8]. Here, we
expanded our analysis to all V-ATPase subunits and we found that LGG/-ATPase subunits were differentially expressed in LGG/IDHmut compared with GBM (p b
al expression of these subunits was examined in LGG/IDHmut samples with respect to the
0·006 (Kolmogorov–Smirnov test). Data are presented as box plots (lower, median and
e subunit genes ATP6V1G2 and ATP6V1G1 in primary or recurrent LGG samples. Each dot
matched initial and recurrent disease of 28 LGG were retrieved from the GlioVis portal
tained by Tukey's Honest Signiﬁcant test. Data are presented as box plots (lower, median
ap showing eight V-ATPase subunits in LGG/IDHwt patients (n = 76; TCGA dataset).
assiﬁers for sorting LGG/IDHmut from GBM cases (training set). Simultaneous down-
ity, 97%; speciﬁcity, 95%; see Table S11). g) LGG/IDHwt cases were annotated as LGG/
omponent analysis (PCA) of V-ATPase genes in LGG/IDHwt cases from the two V-ATPase
e of dead patients according to pathomolecular (LGG/IDHmut and GBM) and V-ATPase
·2, 13·9 and 11·1 months, respectively.
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Fig. 4. The V-ATPase GBM-like signature associates with de-differentiation and upregulation of homeobox genes. a, b) DAVID analysis of pathways associated with LGG/IDHmut (a) or
GBM-like (b) classes in LGG/IDHwt cases. The complete list of genes used to generate these plots is provided in Tables S15, S16. c) Heatmap showing epigenetic enzymes expression in
LGG/IDHwt cases grouped according to the V-ATPase class. For each gene the p value (Kolmogorov-Smirnov test) is indicated. The distribution of homeobox genes expression in each
sample is provided at the bottom. d) Selected homeobox genes were analyzed in an independent set of LGG/IDHwt patients grouped according to the V-ATPase class (Gravendeel
series; n = 40). **, p = 0·001; *, p = 0·02; #, p = 0·03; §, p = 0·006; °, p = 0·04 (Mann-Whitney U test). Data are presented as notched box plots (lower, median and upper
quartile) with whiskers indicating the minimum and maximum values. Each circle represents a sample.
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ferentiated, excitatory phenotype (e.g., V0A1 and V1G2), whereas GBM
and GBM-like LGG/IDHwt cases show upregulation of those associatedFig. 5. NS with elevated V1G1 levels are characterized by upregulation of Homeodomain-c
differentiated cultures. Bars, mean ± SEM (n = 4). b,) Representative NS cultures with high
proteins expression by western blotting. Vinculin was a loading control. c) The homeodomain
Low or High V1G1 levels. Scale bars, 50 μm.
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malian cells, subunit V0A controls targeting of V-ATPase to different
subcellular destinations [20–22]. In human, V0A1 is associated mainlyontaining genes. a) The indicated transcripts were analyzed by qPCR in primary NS or
(NS92 and 97) or low (NS88 and 121) V1G1 expression were analyzed for the indicated
proteins HOXA10, HOXA7 or POU3F2 were analyzed by immunoﬂuorescence in NS with
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brane of non-neuronal cells, whereas V0A2 is overexpressed on the
plasma membrane of ovarian cancer cells where it confers resistance
to chemotherapy [3]. Thus, changes in expression of V0A subunits
may correlate with either the differentiation status, or with tumor-
speciﬁc subcellular activities. V0A subunits are not the only ones we
found modulated, thus additional consequences on V-ATPase biology
can be envisaged. To this regard, the interaction between V1G and
V1C is known to aid dissociation of the V1 sector from the V0 sector
[20] and V1H inhibits the ATPase activity of the catalytic V1 sector
when not assembled on the membrane-embedded V0 pore [23,24].
While the effects of alternative subunits use on pump activity have
not been tested, overall our data imply that aggressive gliomas might
proﬁt from changes in pump assembly, intracellular localization, or
ATPase activity to grow, invade, and resist therapy [3,25–28]. Consider-
ing this, the preferential use of a certain subunit isoform by aggressive
gliomas could be exploited to develop anti-cancer therapeutics that se-
lectively target “oncogenic” V-ATPase in cancer cells. This hypothesis is
supported by evidence from preclinical models of tumorigenesis show-
ing that inhibiting cancer-associated V-ATPases is not lethal [2,29–31].
The ﬁnding that the GBM-like pump is a marker of poor prognosis
for LGG/IDHwt patients independent of age, grade, and molecular pro-
ﬁle (including the chr7/10 alterations) suggests that the pattern of V-
ATPase subunit expression in these tumors might play a functional
role in their biology, perhaps contributing to dictate the number of can-
cer stem cells within the tumor mass. In gliomas harboring a GBM-like
V-ATPase, such hypothesis is consistent with upregulation of
homeobox-containing genes. Although preliminary, our data show
overexpression of homeobox genes in clinical series and in GBM
patient-derived neurospheres with high expression of V1G1. Very few
data that connect V-ATPase and homeobox gene signaling are available.
We showed previously that expression of the neurodevelopmental core
transcription factor POU3F2 was repressed after impairment of V-
ATPase activity using BafA1 [8]. Further, POU3F2 has been previously
demonstrated to be a fundamental reprogramming transcription factor
for GBM stem cells [18], and elevated expression of the homeobox sig-
nature genes in subgroups of GBM [32] or in GBM-derived NS [33] has
been documented. Recently, the HOXA locus was identiﬁed as a driver
for chromosome 7 gains in IDH wild-type GBM, thereby promoting
tumor proliferation and radioresistance [16,34]. In agreement with
this, we found that chromosome 7 gains were more common in LGG/
IDHwt cases expressing the GBM-like pump than in LGG/IDHmut-like
cases. Nevertheless, chr7/10 alterations were not prognostic per se
(Tables S12 and S13); therefore, this event may not completely explain
overexpression of HOXA genes and tumor aggressiveness in LGG/IDHwt
cases. Concluding, our data provide novel insights into gliomagenesis
and uncover a novel mechanism by which GBM and GBM-like LGG
might use these factors to favors de-differentiation towards an
embryonic-like pluripotent state. Further studies are needed to disclose
the mechanisms underpinning homeodomain genes and V-ATPase
interplay.
Author contributions statement
A.T. and I.B. conceived and designed the experiments and prepared
the tables/ﬁgures; A.T. performed bioinformatics analyses; I.B. con-
ducted in vitro experiments; C.M., M.F. and L.O. performed in vivo exper-
iments and analyzed the data; G.G. and A.M.S. performed qPCR, in vitro
experiments and analyzed data; A.D.C., M.C. provided patients' samples
and clinical data; S.B. reviewed patients' series and performed IHC ex-
periments and analyzed the data; T.V. and V.V. drafted and wrote the
manuscript; All authors reviewed the manuscript.
Declaration of interest
There are no conﬂicts of interest to disclose.Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.eAcknowledgments
This work was supported by Fondazione Cariplo (2014-1148 to VV),
Fondazione IRCCS Ca' Granda, and Fondazione INGMGrant inMolecular
Medicine 2014 (to VV). T.V. acknowledges the support of AIRC investi-
gator grant 20661 and Worldwide Cancer Research grant 18-0399.
AMS andMFwere supported by a Fellowship from theDoctorate School
in Molecular and Translational Medicine of Milan University. We are
thankful to Dr. Annamaria Morotti from the Department of Pathophys-
iology and Transplantation (University ofMilan) for helpwith immuno-
blotting and to the INGM Imaging Facility for scientiﬁc and technical
assistance.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ebiom.2019.01.052.References
[1] Cotter K, Stransky L, McGuire C, Forgac M. Recent insights into the structure, regula-
tion, and function of the V-ATPases. Trends Biochem Sci 2015;40(10):611–22.
[2] Stransky L, Cotter K, Forgac M. The function of V-ATPases in cancer. Physiol Rev
2016;96(3):1071–91.
[3] Kulshrestha A, Katara GK, Ginter J, et al. Selective inhibition of tumor cell associated
Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.
Mol Oncol 2016;10(6):789–805.
[4] Wiedmann RM, von Schwarzenberg K, Palamidessi A, et al. The V-ATPase-inhibitor
archazolid abrogates tumor metastasis via inhibition of endocytic activation of the
Rho-GTPase Rac1. Cancer Res 2012;72(22):5976–87.
[5] Cotter K, Liberman R, Sun-Wada G, et al. The a3 isoform of subunit a of the vacuolar
ATPase localizes to the plasma membrane of invasive breast tumor cells and is
overexpressed in human breast cancer. Oncotarget 2016;7(29):46142–57.
[6] Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization classi-
ﬁcation of tumors of the central nervous system: a summary. Acta Neuropathol
2016;131(6):803–20.
[7] Aibaidula A, Chan AK, Shi Z, et al. Adult IDH wild-type lower-grade gliomas should
be further stratiﬁed. Neuro Oncol 2017;19(10):1327–37.
[8] Di Cristofori A, Ferrero S, Bertolini I, et al. The vacuolar H+ ATPase is a novel thera-
peutic target for glioblastoma. Oncotarget 2015;6(19):17514–31.
[9] Ceccarelli M, Barthel FP, Malta TM, et al. Molecular proﬁling reveals biologically dis-
crete subsets and pathways of progression in diffuse glioma. Cell 2016;164(3):
550–63.
[10] Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M. GlioVis data portal for visu-
alization and analysis of brain tumor expression datasets. Neuro Oncol 2017;19(1):
139–41.
[11] Gravendeel LA, KouwenhovenMC, Gevaert O, et al. Intrinsic gene expression proﬁles
of gliomas are a better predictor of survival than histology. Cancer Res 2009;69(23):
9065–72.
[12] Wang X, Teer JK, Tousignant RN, et al. Breast cancer risk and germline genomic pro-
ﬁling of women with neuroﬁbromatosis type 1 who developed breast cancer. Genes
Chromosomes Cancer 2018;57(1):19–27.
[13] Lo Dico A, Martelli C, Valtorta S, et al. Identiﬁcation of imaging biomarkers for the as-
sessment of tumour response to different treatments in a preclinical glioma model.
Eur J Nucl Med Mol Imaging 2015;42(7):1093–105.
[14] Read RD, Fenton TR, Gomez GG, et al. A kinome-wide RNAi screen in Drosophila Glia
reveals that the RIO kinases mediate cell proliferation and survival through TORC2-
Akt signaling in glioblastoma. PLoS Genet 2013;9(2):e1003253.
[15] Reuss DE, Kratz A, Sahm F, et al. Adult IDH wild type astrocytomas biologically and
clinically resolve into other tumor entities. Acta Neuropathol 2015;130(3):407–17.
[16] Kurscheid S, Bady P, Sciuscio D, et al. Chromosome 7 gain and DNA hypermethyla-
tion at the HOXA10 locus are associated with expression of a stem cell related
HOX-signature in glioblastoma. Genome Biol 2015;16:16.
[17] Duan R, Han L,Wang Q, et al. HOXA13 is a potential GBMdiagnostic marker and pro-
motes glioma invasion by activating the Wnt and TGF-beta pathways. Oncotarget
2015;6(29):27778–93.
[18] Suva ML, Rheinbay E, Gillespie SM, et al. Reconstructing and reprogramming the
tumor-propagating potential of glioblastoma stem-like cells. Cell 2014;157(3):
580–94.
[19] Banreti A, Hudry B, Sass M, Saurin AJ, Graba Y. Hox proteins mediate developmental
and environmental control of autophagy. Dev Cell 2014;28(1):56–69.
[20] Toei M, Saum R, Forgac M. Regulation and isoform function of the V-ATPases. Bio-
chemistry 2010;49(23):4715–23.
[21] Finnigan GC, Cronan GE, Park HJ, Srinivasan S, Quiocho FA, Stevens TH. Sorting of the
yeast vacuolar-type, proton-translocating ATPase enzyme complex (V-ATPase):
identiﬁcation of a necessary and sufﬁcient Golgi/endosomal retention signal in
Stv1p. J Biol Chem 2012;287(23):19487–500.
[22] Breton S, Brown D. Regulation of luminal acidiﬁcation by the V-ATPase. Physiology
(Bethesda) 2013;28(5):318–29.V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
biom.2019.01.052
11A. Terrasi et al. / EBioMedicine xxx (2019) xxx[23] Diab H, Ohira M, Liu M, Cobb E, Kane PM. Subunit interactions and requirements for
inhibition of the yeast V1-ATPase. J Biol Chem 2009;284(20):13316–25.
[24] Jefferies KC, Forgac M. Subunit H of the vacuolar (H+) ATPase inhibits ATP hydroly-
sis by the free V1 domain by interaction with the rotary subunit F. J Biol Chem 2008;
283(8):4512–9.
[25] McConnell M, Feng S, ChenW, et al. Osteoclast proton pump regulator Atp6v1c1 en-
hances breast cancer growth by activating the mTORC1 pathway and bone metasta-
sis by increasing V-ATPase activity. Oncotarget 2017;8(29):47675–90.
[26] Liu P, Chen H, Han L, Zou X, Shen W. Expression and role of V1A subunit of V-
ATPases in gastric cancer cells. Int J Clin Oncol 2015;20(4):725–35.
[27] Capecci J, Forgac M. The function of vacuolar ATPase (V-ATPase) a subunit isoforms
in invasiveness of MCF10a and MCF10CA1a human breast cancer cells. J Biol Chem
2013;288(45):32731–41.
[28] McGuire C, Cotter K, Stransky L, Forgac M. Regulation of V-ATPase assembly and
function of V-ATPases in tumor cell invasiveness. Biochim Biophys Acta 2016;1857
(8):1213–8.Please cite this article as: A. Terrasi, I. Bertolini, C. Martelli, et al., Speciﬁc
impacts glioma growth in vivo..., EBioMedicine, https://doi.org/10.1016/j.e[29] Yuan N, Song L, Zhang S, et al. Baﬁlomycin A1 targets both autophagy and apoptosis
pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica 2015;100
(3):345–56.
[30] von Schwarzenberg K, Lajtos T, Simon L, Muller R, Vereb G, Vollmar AM. V-ATPase
inhibition overcomes trastuzumab resistance in breast cancer. Mol Oncol 2014;8
(1):9–19.
[31] Kartner N, Manolson MF. V-ATPase subunit interactions: the long road to therapeu-
tic targeting. Curr Protein Pept Sci 2012;13(2):164–79.
[32] Gallo M, Ho J, Coutinho FJ, et al. A tumorigenic MLL-homeobox network in human
glioblastoma stem cells. Cancer Res 2013;73(1):417–27.
[33] Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and
high epidermal growth factor receptor expression associated with resistance to con-
comitant chemoradiotherapy in glioblastoma. J Clin Oncol 2008;26(18):3015–24.
[34] Cimino PJ, Kim Y, Wu HJ, et al. Increased HOXA5 expression provides a selective ad-
vantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. Genes Dev
2018;32(7–8):512–23.V-ATPase expression sub-classiﬁes IDHwt lower-grade gliomas and
biom.2019.01.052
